At the time of writing, InMed Pharmaceuticals Inc [INM] stock is trading at $5.05, up 2.02%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The INM shares have gain 19.67% over the last week, with a monthly amount drifted -2.70%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
For the past year, the stock price of InMed Pharmaceuticals Inc fluctuated between $2.41 and $15.70. InMed Pharmaceuticals Inc [NASDAQ: INM] shares were valued at $5.05 at the most recent close of the market.
Analyzing the INM fundamentals
According to InMed Pharmaceuticals Inc [NASDAQ:INM], the company’s sales were 4.96M for trailing twelve months, which represents an 40.23% jump. Gross Profit Margin for this corporation currently stands at -1408.68% with Operating Profit Margin at -332.91%, Pretax Profit Margin comes in at -1.37%, and Net Profit Margin reading is -339.28%. To continue investigating profitability, this company’s Return on Assets is posted at -160.82, Equity is -162.3 and Total Capital is 1.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.92 points at the first support level, and at 2.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.22, and for the 2nd resistance point, it is at 9.40.
Ratios To Look Out For
It is important to note that InMed Pharmaceuticals Inc [NASDAQ:INM] has a current ratio of 5.07. Also, the Quick Ratio is 4.22, while the Cash Ratio stands at 0.0. Considering the valuation of this stock, the price to sales ratio is 0.74, the price to book ratio is 0.40.
Transactions by insiders
Recent insider trading involved MANCINI ALEXANDRA DIANE JANET, Consultant, that happened on Jul 31 ’24 when 240.0 shares were sold. Director, HULL ANDREW completed a deal on Feb 21 ’24 to buy 37500.0 shares. Meanwhile, President & CEO ADAMS ERIC A bought 41600.0 shares on Feb 20 ’24.
